为解决阿片类药物成瘾问题，众多研究人员开展 NaV1.8 通道相关非阿片镇痛药研究。Vertex 公司的 Journavx 获批，在临床试验中效果良好且副作用少。这为疼痛治疗带来新方向，强烈推荐科研读者阅读，了解该领域前沿进展。 Vertex 公司的非阿片类急性疼痛药物获 FDA ...

The Food and Drug Administration has granted Fast Track designation to LTG-001 for the treatment of acute pain.

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments ...

LatigoBio是美国一家非阿片类止痛药研发商，主打项目LTG-001是一种口服选择性Nav1.8抑制剂，目前正在健康志愿者中进行1期临床试验，旨在治疗急性和慢性疼痛。近日，LatigoBio获得1.5亿美元B轮融资，Alexandria Venture Investments、5AM Ventures、Foresite Capital、Westlake Village BioPartners、 ...

Shanghai Wennai Pharmaceutical Technology Co. Ltd. has disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of acute and chronic pain.

California-based Latigo Biotherapeutics, a biotech developing non-opioid pain treatments, has closed $150 million in a Series B financing.

Some of the main targets of these injured nerves are the voltage gated sodium channels NaV1.7 and NaV1.8. The McDougall Lab has found that opening of NaV1.8 channels causes joint pain. We have shown ...

The oral NaV1.8 inhibitor has been cleared under the Journavx brand name with a broad label to treat adults with moderate-to-severe acute pain - for example, after trauma or surgery - and works by ...

Vertex's candidate, called VX-548, targets NaV1.8 sodium channels, which are thought to play a role in relaying pain signals to the spinal cord from peripheral nerves. It has been shown to be ...